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1. INTRODUCTION {#eci12903-sec-0005}
===============

As a life‐threatening disease, cancer has increasingly been a heavy burden of healthcare system.[1](#eci12903-bib-0001){ref-type="ref"}, [2](#eci12903-bib-0002){ref-type="ref"} The failure of cancer therapy and poor outcomes are mostly owing to the development of local invasion and distant metastasis. Activating of invasion and metastasis has been demonstrated as one of the most important hallmark capabilities of cancer.[1](#eci12903-bib-0001){ref-type="ref"} To date, researchers have paid tremendous attention to the biological behaviour of cancer cells, aiming at finding potential therapeutic targets.

Invasion and metastasis are considered as complex processes involving detachment of cancer cell from primary tumour site and formation of new tumour foci in distant organs.[3](#eci12903-bib-0003){ref-type="ref"}, [4](#eci12903-bib-0004){ref-type="ref"}, [5](#eci12903-bib-0005){ref-type="ref"} Epithelial‐mesenchymal transition (EMT), a developmental regulatory programme, identified as transformed epithelial cells loss epithelial constraints and then acquire the abilities to invade, resist apoptosis and metastasis, which is believed to play a vital role in broadly regulating invasion and metastasis.[2](#eci12903-bib-0002){ref-type="ref"}, [6](#eci12903-bib-0006){ref-type="ref"}, [7](#eci12903-bib-0007){ref-type="ref"}, [8](#eci12903-bib-0008){ref-type="ref"}, [9](#eci12903-bib-0009){ref-type="ref"} Cadherins are a family of calcium‐dependent glycoproteins, which responsible for Ca^2+^‐dependent cell‐cell adhesions. Of the members of this family, N‐cadherin (neuronal cadherin or cadherin‐2), a transmembrane glycoprotein, which is normally expressed in neuroectodermal and mesenchymal‐derived tissues, plays crucial role in lots of processes, such as cell‐cell adhesion, embryogenesis, gastrulation, neurulation, migration and invasion.[4](#eci12903-bib-0004){ref-type="ref"}, [10](#eci12903-bib-0010){ref-type="ref"}, [11](#eci12903-bib-0011){ref-type="ref"}, [12](#eci12903-bib-0012){ref-type="ref"}, [13](#eci12903-bib-0013){ref-type="ref"} Today, N‐cadherin is regarded as a vital marker of EMT.[14](#eci12903-bib-0014){ref-type="ref"} Neoexpression or upregulated expression of N‐cadherin has been reported to accelerate migration and invasion of cancer cells, which showed a contrary function to those of E‐cadherin.[15](#eci12903-bib-0015){ref-type="ref"}, [16](#eci12903-bib-0016){ref-type="ref"}, [17](#eci12903-bib-0017){ref-type="ref"}, [18](#eci12903-bib-0018){ref-type="ref"} This process of reciprocally downregulating E‐cadherin and upregulating N‐cadherin is known as cadherin switching that characterizes EMT.[19](#eci12903-bib-0019){ref-type="ref"} Cadherin switching is a necessary procedure during the course of development, while it will lead to an aggressive tumour cell phenotype and enable tumour cells obtain ability of migration from primary site and metastasis to distant tissues.[20](#eci12903-bib-0020){ref-type="ref"} Study reveals that N‐cadherin‐positive cancer cells are capable of building cell‐cell adhesion with stromal cells that express N‐cadherin, thus facilitating invasion process.[21](#eci12903-bib-0021){ref-type="ref"} Some studies indicate that N‐cadherin boosts the combination of fibroblast growth factor (FGF) with the receptor to initiate FGFR signal transduction, thereby inducing signalling cascades that promote migration and invasion of cancer cells.[22](#eci12903-bib-0022){ref-type="ref"} Furthermore, studies have shown that N‐cadherin promotes cells survival and protects cancer cells from apoptosis by activating the phosphatidylinositol 3‐kinase (PI3K)‐AKT (also known as protein kinase B) pathway.[17](#eci12903-bib-0017){ref-type="ref"}, [23](#eci12903-bib-0023){ref-type="ref"}, [24](#eci12903-bib-0024){ref-type="ref"} Therefore, N‐cadherin presents distinct functions from its adhesion activity.

Nevertheless, the prognostic role of N‐cadherin in tumours still remains controversially. Some studies suggested that expression of N‐cadherin was generally upregulated in prostate, breast cancer and urothelial tumours, and was associated with poorer clinical outcomes.[10](#eci12903-bib-0010){ref-type="ref"}, [11](#eci12903-bib-0011){ref-type="ref"}, [25](#eci12903-bib-0025){ref-type="ref"} In addition, the upregulation of N‐cadherin was significantly related with postoperative recurrence in hepatocellular carcinoma (HCC) patients.[26](#eci12903-bib-0026){ref-type="ref"} However, it was also reported that the expression of N‐cadherin was decreased in glioblastoma, ovarian carcinoma, osteosarcoma and HCC, which may provide a hypothesis that N‐cadherin serves as a tumour suppressor and its downregulation links to poor surgical outcomes.[15](#eci12903-bib-0015){ref-type="ref"}, [27](#eci12903-bib-0027){ref-type="ref"}, [28](#eci12903-bib-0028){ref-type="ref"}, [29](#eci12903-bib-0029){ref-type="ref"} Therefore, this meta‐analysis was conducted to assess the relationship of N‐cadherin expression with clinicopathological features and prognosis of different carcinomas, especially in epithelial‐derived solid tumours.

2. MATERIALS AND METHODS {#eci12903-sec-0006}
========================

2.1. Primary search strategy {#eci12903-sec-0007}
----------------------------

The Pubmed/MELINE and EMBASE databases were used for related publications search by variably combining the terms "cancer \[Title/Abstract\]," "tumour \[Title/Abstract\]," "carcinoma \[Title/Abstract\]," "neoplasm \[Title/Abstract\]" and "N‐cadherin \[Title/Abstract\]," without any limitation of publication date. The most recent search update was conducted on 23 February 2017. To avoid missing additional studies, the references of all eligible studies were further explored in these databases. PRISMA and the broader EQUATOR guidelines were referred to in the reporting of our study to comply with the standard of meta‐analysis.[30](#eci12903-bib-0030){ref-type="ref"}

2.2. Inclusion and exclusion criteria {#eci12903-sec-0008}
-------------------------------------

The included studies were required to meet the following criteria: (i) the patients with solid tumours included in these studies were diagnosed histopathologically; (ii) the correlation of N‐cadherin expression and solid tumours was evaluated; (iii) clinicopathological features, 3/5‐year survival, OS or Kaplan‐Meier survival curves were investigated; and (iv) full text was written in English. Studies were excluded if (i) the study was published in conference abstract, letters, editorials, reviews, expert opinion or case reports; (ii) studies of animals or cell lines; (iii) the relevant clinicopathological features or outcomes of patients were not able to be acquired for necessary analysis; (iv) overlapped or duplicated studies.

2.3. Data extraction {#eci12903-sec-0009}
--------------------

Data were carefully retrieved independently by 2 reviewers from all the eligible studies, using a standardized form with the following characteristics: author, year, country, study design, number of patients, mean age, method used for evaluating expression of N‐cadherin, antibody source, definition of N‐cadherin positive, expression rate of N‐cadherin, median follow‐up time, clinicopathological features and survival data. Discrepancies between 2 reviewers were solved by discussing until agreement was reached with the third reviewer. Quality assessment of included studies was conducted on the basis of the Newcastle‐Ottawa quality assessment scale (NOS scale). Six points or higher were regarded as high quality.

2.4. Statistical analysis {#eci12903-sec-0010}
-------------------------

Included studies were divided into 7 groups for analysing the prognostic value of N‐cadherin expression in solid tumour patients regarding histological grade, lymph node status, angiolymphatic invasion, distant metastasis, clinical stage, 3‐year survival, 5‐year survival and OS. Clinicopathological features were synthesized using the risk ratio (RR) as the calculating measure, while the survival outcome data using the hazard ratio (HR) as calculating measure. RR/HR with 95% confidence interval (CI) value was performed to quantitatively evaluate how increased N‐cadherin expression impacts the prognosis of solid tumour patients. Reported RR/HR and their 95% CI were directly extracted from included studies. If RR/HR and 95% CIs were not available in the original articles, the methods demonstrated by Parmer et al[30](#eci12903-bib-0030){ref-type="ref"} and Tierney et al[31](#eci12903-bib-0031){ref-type="ref"} were applied to calculate RR/HR and 95% CIs. Moreover, when the exploitable data were presented in the figure form, Engauge Digitizer version 4.1 (free software downloading from <http://sourceforge.net>) was applied to extract data from Kaplan‐Meier curves thereby obtaining HR and 95% CIs. Heterogeneities of included studies were assessed using *I* ^2^ metric and Q statistic. If heterogeneity was significantly obvious (*I* ^2^ \> 50% or *P* \< .1), a random effect model was used. Otherwise, a fixed effect model would be chosen (*I* ^2^ \< 50% or *P* \> .1).The pooled RRs/HRs and 95% CIs were presented in forest plots. If the 95% CIs of RR/HR did not cover the value 1 with *P* \< .05, the difference between groups would be regarded as statistically significant. In addition, funnel plots (Begg\'s test) and Egger\'s linear regression method (Egger\'s test) were performed to evaluate the publication bias through assessing the asymmetry of funnel plots (if *P* \< .05, considering to be statistically significant).[32](#eci12903-bib-0032){ref-type="ref"} All statistical analyses in this meta‐analysis were performed using STATA version 12.0 (STATA corporation, College Station, TS, USA).

3. RESULTS {#eci12903-sec-0011}
==========

3.1. Study selection and characteristics {#eci12903-sec-0012}
----------------------------------------

According to the initial search algorithm, total 4476 studies were screened out, and 389 candidate studies were read in full. Eventually, a total of 36 publications were included in this meta‐analysis, and the other 353 studies were out of scope, as shown in Figure [1](#eci12903-fig-0001){ref-type="fig"}. A total of 5705 patients were included in this study, ranging from 38 to 1035 patients per study, the main characteristics and NOS scale of eligible studies were presented in Table [1](#eci12903-tbl-0001){ref-type="table-wrap"}. Most of studies were prospective cohort studies (n = 25), and 11 studies were retrospective cohort studies. The median follow‐up time varied from 10.1 months to 125 months.

![Flow chart of the literature search and selection of included studies](ECI-48-na-g001){#eci12903-fig-0001}

###### 

Characteristics of the eligible studies

  First author (ref)                                             Year   Country   Study design   Number (M/F)    Mean age   Method   Antibody source                    Definition of N‐cadherin positive                 Expression rate (%)   Median follow‐up (m)   Quality stars (NOS)
  -------------------------------------------------------------- ------ --------- -------------- --------------- ---------- -------- ---------------------------------- ------------------------------------------------- --------------------- ---------------------- ---------------------
  HNC (n = 6)                                                                                                                                                                                                                                                          
  Nguyen, P.T. [39](#eci12903-bib-0039){ref-type="ref"}          2011   Japan     Retro.         80 (NR)         NR         IHC      BD Biosciences                     ≥20%                                              NR                    NR                     7
  Gasparotto, D. [41](#eci12903-bib-0041){ref-type="ref"}        2011   Italy     Pro.           69 (65/4)       NR         IHC      Novocastra                         ≥Median expression level                          NR                    45                     8
  Ding, L. [43](#eci12903-bib-0043){ref-type="ref"}              2014   China     Pro.           50 (25/25)      53.5       IHC      Zymed                              ≥20%                                              NR                    60.34                  9
  Mohan, A. [56](#eci12903-bib-0056){ref-type="ref"}             2006   India     Retro.         62 (38/24)      2.67       IHC      Upstate Cell Signaling Solutions   ≥5%                                               93.5                  NR                     8
  Luo, W.R. [58](#eci12903-bib-0058){ref-type="ref"}             2011   China     Pro.           122 (92/30)     47.6       IHC      Zymed                              IRS ≥ 6[a](#eci12903-note-0003){ref-type="fn"}    NR                    51.9                   9
  Greco, A. [67](#eci12903-bib-0067){ref-type="ref"}             2015   Italy     Pro.           82 (70/12)      61         IHC      Santa Cruz Biotechnology           NR                                                NR                    NR                     7
  Breast cancer (n = 7)                                                                                                                                                                                                                                                
  Aleskandarany, M.A. [32](#eci12903-bib-0032){ref-type="ref"}   2014   England   Pro.           1035 (NR)       54         IHC      Sigma                              NR                                                NR                    125                    8
  Choi, Y. [33](#eci12903-bib-0033){ref-type="ref"}              2013   Korea     Retro.         389 (NR)        50.6       IHC      Invitrogen                         ≥10%                                              NR                    NR                     7
  Markiewicz, A. [34](#eci12903-bib-0034){ref-type="ref"}        2014   Poland    Pro.           108 (NR)        60         IHC      Dako                               ≥10%                                              NR                    28.8                   8
  ElMoneim, H.M.A. [35](#eci12903-bib-0035){ref-type="ref"}      2011   Egypt     Retro.         132 (NR)        52.67      IHC      Dako                               ≥10%                                              NR                    NR                     7
  Kovács, A. [37](#eci12903-bib-0037){ref-type="ref"}            2003   England   Pro.           100 (NR)        NR         IHC      Zymed                              ≥20%                                              NR                    NR                     7
  Cao, Y.W. [38](#eci12903-bib-0038){ref-type="ref"}             2014   China     Retro.         200 (NR)        NR         IHC      Abcam                              IRS \> 3                                          NR                    NR                     6
  Carvalho, S.T. [64](#eci12903-bib-0064){ref-type="ref"}        2011   Brazil    Pro.           82 (NR)         NR         IHC      BD Biosciences                     ≥10%                                              NR                    120                    8
  Lung cancer (n = 7)                                                                                                                                                                                                                                                  
  Li, X.X. [36](#eci12903-bib-0036){ref-type="ref"}              2015   China     Pro.           65 (44/21)      59         IHC      Abcam                              IRS ≥ 3                                           35.4                  30.17                  8
  Nakashima, T. [40](#eci12903-bib-0040){ref-type="ref"}         2003   Japan     Pro.           150 (NR)        NR         IHC      BD Bioscience                      ≥20%                                              30.6                  41.4                   7
  Hui, L. [42](#eci12903-bib-0042){ref-type="ref"}               2013   China     Pro.           120 (81/39)     60         IHC      Santa Cruz Biotechnology           IRS ≥ 2                                           30.7                  30.8                   8
  Zhou, Y. [57](#eci12903-bib-0057){ref-type="ref"}              2016   China     Pro.           153 (141/12)    NR         IHC      Abcam                              IRS \> 4                                          79.08                 57                     7
  Grinberg‐Rashi, H. [59](#eci12903-bib-0059){ref-type="ref"}    2009   Israel    Pro.           107 (76/31)     61.06      IHC      Dako                               Mesothelioma as positive control                  NR                    34                     8
  Liu, S. [63](#eci12903-bib-0063){ref-type="ref"}               2013   China     Pro.           113 (61/52)     60.3       IHC      Santa Cruz Biotechnology           ≥10%                                              40.7                  NR                     8
  Miao, Y. [66](#eci12903-bib-0066){ref-type="ref"}              2012   China     Pro.           105 (63/42)     60.4       IHC      Abcam                              ≥10%                                              44.8                  NR                     8
  Cancer of digestive system (n = 7)                                                                                                                                                                                                                                   
  Kamikihara, T. [44](#eci12903-bib-0044){ref-type="ref"}        2012   Japan     Pro.           146 (99/47)     63         IHC      Dako                               ≥5%                                               21.2                  43.2                   9
  Araki, K. [45](#eci12903-bib-0045){ref-type="ref"}             2011   Japan     Pro.           38 (NR)         NR         IHC      Invitrogen Corp.                   NR                                                23.7                  NR                     7
  Nakajima, S. [49](#eci12903-bib-0049){ref-type="ref"}          2004   Japan     Pro.           40 (NR)         66.3       IHC      Zymed                              ≥10%                                              32.5                  10.1                   7
  Guo, S. [50](#eci12903-bib-0050){ref-type="ref"}               2013   China     Retro.         76 (47/29)      65         IHC      Santa Cruz Biotechnology           IRS ≥ 5                                           32.9                  NR                     7
  Cho, S.B. [53](#eci12903-bib-0053){ref-type="ref"}             2008   Korea     Pro.           68 (55/13)      60         IHC      Dako                               ≥30%                                              NR                    30                     6
  Jie, D. [54](#eci12903-bib-0054){ref-type="ref"}               2013   China     Pro.           108 (65/43)     54         IHC      R&D Systems                        IRS ≥ 1                                           41.7                  NR                     7
  Fu, H. [65](#eci12903-bib-0065){ref-type="ref"}                2016   China     Retro.         74 (63/11)      NR         IHC      NR                                 IRS ≥ 2                                           36.48                 NR                     7
  Urothelial carcinoma (n = 3)                                                                                                                                                                                                                                         
  Abufaraj, M. [51](#eci12903-bib-0051){ref-type="ref"}          2016   Italy     Pro.           678 (380/298)   NR         IHC      Dako                               Higher than normal bladder and prostate tissues   43.1                  37.5                   9
  Fondrevelle, M.E. [60](#eci12903-bib-0060){ref-type="ref"}     2009   France    Pro.           70 (52/18)      69         IHC      Zymed                              Higher than normal myocardium tissue              17.14                 30                     8
  Baumgart, E. [61](#eci12903-bib-0061){ref-type="ref"}          2007   America   Pro.           572 (NR)        NR         IHC      Zymed                              NR                                                8.2                   61.2                   8
  Prostate cancer (n = 2)                                                                                                                                                                                                                                              
  Liu, GL. [46](#eci12903-bib-0046){ref-type="ref"}              2014   China     Retro.         59 (NR)         68         IHC      Bioss Biotechnology                ≥5%                                               NR                    NR                     7
  Drivalos, A. [47](#eci12903-bib-0047){ref-type="ref"}          2015   Greece    Retro.         157 (NR)        66         IHC      Dako                               IRS \> 3                                          NR                    NR                     7
  Gynecologic Cancer (n = 4)                                                                                                                                                                                                                                           
  Li, B. [48](#eci12903-bib-0048){ref-type="ref"}                2016   China     Retro.         127 (NR)        NR         IHC      Santa Cruz Biotechnology           IRS ≥ 3                                           3.1                   72                     8
  Ma, Y. [52](#eci12903-bib-0052){ref-type="ref"}                2015   China     Retro.         81 (NR)         48.1       IHC      Beijing Zhong Shan Biotechnology   ≥10%                                              28.4                  NR                     7
  Marques, F.R. [56](#eci12903-bib-0056){ref-type="ref"}         2004   Brazil    Pro.           47 (NR)         51         IHC      Zymed                              ≥10%                                              NR                    48                     7
  Do, TV. [62](#eci12903-bib-0062){ref-type="ref"}               2008   America   Pro.           40 (NR)         62.4       IHC      Invitrogen                         IRS ≥ 1.5                                         NR                    NR                     6

Abbreviations: F, female; IRS, immuno‐reactive score; IHC, immunohistochemistry; m, month; M, male; NOS, Newcastle‐Ottawa quality assessment scale; NR, not reported; Pro., prospective study; Retro., retrospective study; ref, reference.

IRS = percentage score × intensity score. Percentage score of stained tumour cells is considered as follows: no staining (score = 0), \<10% stained (score = 1), 10%‐50% stained (score = 2), 51%‐80% stained (score = 3) and 81%‐100% stained (score = 4). Intensity score is estimated as no staining (score = 0), weak staining (score = 1), moderate staining (score = 2) and strong staining (score = 3).
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Among the eligible studies, 36 studies compared the correlation of clinicopathological features and N‐cadherin expression, including lymph node metastasis (n = 21), histological grade (n = 21), angiolymphatic invasion (n = 8), distant metastasis (n = 7) and clinical stage (n = 14). In addition, 10 studies assessed the association of 3‐year survival and N‐cadherin positivity, 8 studies for 5‐year survival and 22 studies for OS. In terms of NOS scale, 3 articles scored 6 points, 16 articles scored 7 points, 13 articles scored 8 points and 4 articles scored 9 points, hence, all of these inclusive studies were regarded as qualified enough for meta‐analysis.

3.2. Lymph node metastasis {#eci12903-sec-0013}
--------------------------

Lymph node metastasis was evaluated in 21 studies with 3900 patients (positive lymph node metastasis versus negative lymph node metastasis).[33](#eci12903-bib-0033){ref-type="ref"}, [34](#eci12903-bib-0034){ref-type="ref"}, [35](#eci12903-bib-0035){ref-type="ref"}, [36](#eci12903-bib-0036){ref-type="ref"}, [37](#eci12903-bib-0037){ref-type="ref"}, [38](#eci12903-bib-0038){ref-type="ref"}, [39](#eci12903-bib-0039){ref-type="ref"}, [40](#eci12903-bib-0040){ref-type="ref"}, [41](#eci12903-bib-0041){ref-type="ref"}, [42](#eci12903-bib-0042){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [46](#eci12903-bib-0046){ref-type="ref"}, [47](#eci12903-bib-0047){ref-type="ref"}, [48](#eci12903-bib-0048){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [51](#eci12903-bib-0051){ref-type="ref"}, [52](#eci12903-bib-0052){ref-type="ref"}, [53](#eci12903-bib-0053){ref-type="ref"} Pooled RR indicated that increased N‐cadherin apt to cause lymph node metastasis (RR = 1.16, 95%CI \[1.00, 1.35\], *I* ^2^ = 57.6%, *P *=* *.806; Figure [2](#eci12903-fig-0002){ref-type="fig"}A). Thus, a random effect mode was employed due to obvious heterogeneity. According to the subgroup analyses of different tumour types, N‐cadherin overexpression in prostate cancer contributed to a significantly positive lymph node metastasis (RR = 2.94, 95%CI \[1.29, 6.70\]) in 2 studies with 216 patients.[47](#eci12903-bib-0047){ref-type="ref"}, [48](#eci12903-bib-0048){ref-type="ref"}

![Forrest plots of risk ratios (RRs) for correlation between N‐cadherin upregulation and clinicopathological features. A, Lymph node metastasis; B, histological grade; C, angiolymphatic invasion](ECI-48-na-g002){#eci12903-fig-0002}

3.3. Histological grade {#eci12903-sec-0014}
-----------------------

A total of 21 studies with 2995 patients assessed the impact of N‐cadherin expression and histological grade (poor differentiation vs well/moderate differentiation).[34](#eci12903-bib-0034){ref-type="ref"}, [35](#eci12903-bib-0035){ref-type="ref"}, [36](#eci12903-bib-0036){ref-type="ref"}, [38](#eci12903-bib-0038){ref-type="ref"}, [39](#eci12903-bib-0039){ref-type="ref"}, [40](#eci12903-bib-0040){ref-type="ref"}, [41](#eci12903-bib-0041){ref-type="ref"}, [42](#eci12903-bib-0042){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [48](#eci12903-bib-0048){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [51](#eci12903-bib-0051){ref-type="ref"}, [52](#eci12903-bib-0052){ref-type="ref"}, [53](#eci12903-bib-0053){ref-type="ref"}, [54](#eci12903-bib-0054){ref-type="ref"}, [55](#eci12903-bib-0055){ref-type="ref"}, [56](#eci12903-bib-0056){ref-type="ref"}, [57](#eci12903-bib-0057){ref-type="ref"}, [58](#eci12903-bib-0058){ref-type="ref"} Pooled RR showed that increased N‐cadherin expression was significantly associated with worse differentiation (RR = 1.36, 95% CI \[1.14, 1.62\]) (Figure [2](#eci12903-fig-0002){ref-type="fig"}B). Because of obvious heterogeneity, random effect model was performed (*I* ^2^ = 65.1%, *P *=* *.000). Subgroup analyses of different tumour types showed N‐cadherin upregulation was significantly associated with worse differentiation of breast cancer (RR = 1.47, 95% CI \[1.24, 1.74\]), while no statistically significant relationships were found between upregulation of N‐cadherin and oestrogen receptor (ER), progesterone receptor (PR) or HER2 expression in breast cancer in 5 studies with 821 patients (RR = 0.79, 95% CI \[0.61, 1.02\]; RR = 0.88, 95% CI \[0.73, 1.06\]; RR = 1.04, 95% CI \[0.80, 1.34\]; respectively) (Figure [S1](#eci12903-sup-0001){ref-type="supplementary-material"}A).[33](#eci12903-bib-0033){ref-type="ref"}, [34](#eci12903-bib-0034){ref-type="ref"}, [36](#eci12903-bib-0036){ref-type="ref"}, [38](#eci12903-bib-0038){ref-type="ref"}, [39](#eci12903-bib-0039){ref-type="ref"}

3.4. Angiolymphatic invasion {#eci12903-sec-0015}
----------------------------

Pooled RR of 8 inclusive studies with 2239 patients showed the upregulation of N‐cadherin was significantly correlated with angiolymphatic invasion (RR = 1.19, 95%CI \[1.06, 1.34\]) (Figure [2](#eci12903-fig-0002){ref-type="fig"}C).[34](#eci12903-bib-0034){ref-type="ref"}, [36](#eci12903-bib-0036){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [52](#eci12903-bib-0052){ref-type="ref"}, [53](#eci12903-bib-0053){ref-type="ref"}, [57](#eci12903-bib-0057){ref-type="ref"} A subgroup analysis suggested that upregulation of N‐cadherin was significantly associated with angiolymphatic invasion in cancers of digestive system in 2 studies with 186 patients (RR = 1.37, 95%CI \[1.07, 1.77\]).[45](#eci12903-bib-0045){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"} No obvious heterogeneity was observed, hence a fixed effect model was employed (*I* ^2^ = 0.0%, *P *=* *.629; Table [2](#eci12903-tbl-0002){ref-type="table-wrap"}).

###### 

Summary of the outcomes presented in this meta‐analysis

  Group                     No. of studies   No. of total patients   RR/HR (95% CI) (N‐cad overexpression vs N‐cad normal expression)   *P* for heterogeneity   *I* ^2^   References
  ------------------------- ---------------- ----------------------- ------------------------------------------------------------------ ----------------------- --------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lymph node metastasis     21               3900                    1.16 (1.00, 1.35)                                                  .001                    57.6%     [32](#eci12903-bib-0032){ref-type="ref"}, [33](#eci12903-bib-0033){ref-type="ref"}, [34](#eci12903-bib-0034){ref-type="ref"}, [35](#eci12903-bib-0035){ref-type="ref"}, [36](#eci12903-bib-0036){ref-type="ref"}, [37](#eci12903-bib-0037){ref-type="ref"}, [38](#eci12903-bib-0038){ref-type="ref"}, [39](#eci12903-bib-0039){ref-type="ref"}, [40](#eci12903-bib-0040){ref-type="ref"}, [41](#eci12903-bib-0041){ref-type="ref"}, [42](#eci12903-bib-0042){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [46](#eci12903-bib-0046){ref-type="ref"}, [47](#eci12903-bib-0047){ref-type="ref"}, [48](#eci12903-bib-0048){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [51](#eci12903-bib-0051){ref-type="ref"}, [52](#eci12903-bib-0052){ref-type="ref"}
  Histological grade        21               2995                    1.36 (1.14, 1.62)                                                  .000                    65.1%     [33](#eci12903-bib-0033){ref-type="ref"}, [34](#eci12903-bib-0034){ref-type="ref"}, [35](#eci12903-bib-0035){ref-type="ref"}, [37](#eci12903-bib-0037){ref-type="ref"}, [38](#eci12903-bib-0038){ref-type="ref"}, [39](#eci12903-bib-0039){ref-type="ref"}, [40](#eci12903-bib-0040){ref-type="ref"}, [41](#eci12903-bib-0041){ref-type="ref"}, [42](#eci12903-bib-0042){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [47](#eci12903-bib-0047){ref-type="ref"}, [48](#eci12903-bib-0048){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [51](#eci12903-bib-0051){ref-type="ref"}, [52](#eci12903-bib-0052){ref-type="ref"}, [53](#eci12903-bib-0053){ref-type="ref"}, [54](#eci12903-bib-0054){ref-type="ref"}, [55](#eci12903-bib-0055){ref-type="ref"}, [56](#eci12903-bib-0056){ref-type="ref"}, [57](#eci12903-bib-0057){ref-type="ref"}
  Angiolymphatic invasion   8                2239                    1.19 (1.06, 1.34)                                                  .629                    0.0%      [33](#eci12903-bib-0033){ref-type="ref"}, [35](#eci12903-bib-0035){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [48](#eci12903-bib-0048){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [51](#eci12903-bib-0051){ref-type="ref"}, [52](#eci12903-bib-0052){ref-type="ref"}, [56](#eci12903-bib-0056){ref-type="ref"}
  Distant metastasis        7                434                     1.43 (0.99, 2.05)                                                  .382                    5.9%      [36](#eci12903-bib-0036){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [46](#eci12903-bib-0046){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [54](#eci12903-bib-0054){ref-type="ref"}, [58](#eci12903-bib-0058){ref-type="ref"}
  Clinical stage            14               1479                    1.32 (1.06, 1.64)                                                  .000                    68.9%     [35](#eci12903-bib-0035){ref-type="ref"}, [36](#eci12903-bib-0036){ref-type="ref"}, [38](#eci12903-bib-0038){ref-type="ref"}, [39](#eci12903-bib-0039){ref-type="ref"}, [42](#eci12903-bib-0042){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [47](#eci12903-bib-0047){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [53](#eci12903-bib-0053){ref-type="ref"}, [54](#eci12903-bib-0054){ref-type="ref"}, [57](#eci12903-bib-0057){ref-type="ref"}, [58](#eci12903-bib-0058){ref-type="ref"}
  3‐year survival           10               2370                    1.78 (1.51, 2.10)                                                  .174                    29.4%     [32](#eci12903-bib-0032){ref-type="ref"}, [42](#eci12903-bib-0042){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [54](#eci12903-bib-0054){ref-type="ref"}, [58](#eci12903-bib-0058){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"}, [60](#eci12903-bib-0060){ref-type="ref"}, [61](#eci12903-bib-0061){ref-type="ref"}, [62](#eci12903-bib-0062){ref-type="ref"}
  5‐year survival           8                2180                    1.57 (1.17, 2.10)                                                  .019                    58.2%     [32](#eci12903-bib-0032){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [54](#eci12903-bib-0054){ref-type="ref"}, [58](#eci12903-bib-0058){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"}, [61](#eci12903-bib-0061){ref-type="ref"}, [62](#eci12903-bib-0062){ref-type="ref"}
  OS                        22               4081                    1.32 (1.20, 1.44)                                                  .007                    48.0%     [32](#eci12903-bib-0032){ref-type="ref"}, [40](#eci12903-bib-0040){ref-type="ref"}, [41](#eci12903-bib-0041){ref-type="ref"}, [42](#eci12903-bib-0042){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [48](#eci12903-bib-0048){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [51](#eci12903-bib-0051){ref-type="ref"}, [54](#eci12903-bib-0054){ref-type="ref"}, [57](#eci12903-bib-0057){ref-type="ref"}, [58](#eci12903-bib-0058){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"}, [60](#eci12903-bib-0060){ref-type="ref"}, [61](#eci12903-bib-0061){ref-type="ref"}, [62](#eci12903-bib-0062){ref-type="ref"}, [63](#eci12903-bib-0063){ref-type="ref"}, [64](#eci12903-bib-0064){ref-type="ref"}, [65](#eci12903-bib-0065){ref-type="ref"}, [66](#eci12903-bib-0066){ref-type="ref"}, [67](#eci12903-bib-0067){ref-type="ref"}

HR, hazard ratio; RR, risk ratio; OS, overall survival.
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3.5. Distant metastasis {#eci12903-sec-0016}
-----------------------

Distant metastasis was investigated in 7 studies with 434 patients.[37](#eci12903-bib-0037){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [47](#eci12903-bib-0047){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [51](#eci12903-bib-0051){ref-type="ref"}, [55](#eci12903-bib-0055){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"} Pooled RR showed a no statistically significant relationship between N‐cadherin upregulation and distant metastasis (RR = 1.43, 95%CI \[0.99, 2.05\]) (Figure [3](#eci12903-fig-0003){ref-type="fig"}A). A fixed effect model was used for observing no obvious heterogeneity (*I* ^2^ = 5.9%, *P *=* *.382). Subgroup analysis in cancers of digestive system demonstrated significant association between N‐cadherin upregulation and distant metastasis, in 4 studies with 370 patients (RR = 1.90, 95%CI \[1.01, 3.59\]).[45](#eci12903-bib-0045){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [51](#eci12903-bib-0051){ref-type="ref"}, [55](#eci12903-bib-0055){ref-type="ref"}

![Forrest plots of risk ratio (RRs) for correlation between N‐cadherin upregulation and clinicopathological features. A, Distant metastasis; B, clinical stage](ECI-48-na-g003){#eci12903-fig-0003}

3.6. Clinical Stage {#eci12903-sec-0017}
-------------------

A total of 14 studies with 1479 patients discussed the relationship between N‐cadherin upregulation and clinical stage (III/IV vs I/II).[36](#eci12903-bib-0036){ref-type="ref"}, [37](#eci12903-bib-0037){ref-type="ref"}, [39](#eci12903-bib-0039){ref-type="ref"}, [40](#eci12903-bib-0040){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [46](#eci12903-bib-0046){ref-type="ref"}, [48](#eci12903-bib-0048){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [54](#eci12903-bib-0054){ref-type="ref"}, [55](#eci12903-bib-0055){ref-type="ref"}, [58](#eci12903-bib-0058){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"} Pooled RR showed higher N‐cadherin expression was related to advanced clinical stage (RR = 1.32, 95% CI \[1.06, 1.64\]) (Figure [3](#eci12903-fig-0003){ref-type="fig"}B). A random effect model was performed for obvious heterogeneity (*I* ^2^ = 68.9%, *P *=* *.000).Subgroup analysis of head and neck cancers (HNC) indicated an association between N‐cadherin upregulation and advanced clinical stages, in 3 studies with 252 patients (RR = 1.59, 95% CI \[1.33, 1.91\]).[40](#eci12903-bib-0040){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"}

3.7. 3‐year and 5‐year survival {#eci12903-sec-0018}
-------------------------------

Quantitative analysis of pooled RR confirmed that upregulation of N‐cadherin was shown to be an unfavourable prognostic marker of 3‐year survival (HR = 1.78, 95%CI \[1.51, 2.10\]) with no obvious heterogeneity in 10 studies with 2370 patients (Figure [4](#eci12903-fig-0004){ref-type="fig"}A).[33](#eci12903-bib-0033){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [55](#eci12903-bib-0055){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"}, [60](#eci12903-bib-0060){ref-type="ref"}, [61](#eci12903-bib-0061){ref-type="ref"}, [62](#eci12903-bib-0062){ref-type="ref"}, [63](#eci12903-bib-0063){ref-type="ref"} Subgroup analysis showed N‐cadherin overexpression was related to worse 3‐year survival in HNC (HR = 2.24, 95%CI \[1.31, 3.81\]), nonsmall cell lung cancer (NSCLC) (HR = 2.02, 95%CI \[1.52, 2.70\]) and cancer of digestive system (HR = 2.19, 95%CI \[1.35, 3.56\]). Similar result was also found in 5‐year survival (HR = 1.57, 95%CI \[1.17, 2.10\]) in 8 studies with 2180 patients (Figure [4](#eci12903-fig-0004){ref-type="fig"}B).[33](#eci12903-bib-0033){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [55](#eci12903-bib-0055){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"}, [60](#eci12903-bib-0060){ref-type="ref"}, [62](#eci12903-bib-0062){ref-type="ref"}, [63](#eci12903-bib-0063){ref-type="ref"} Subgroup analysis indicated the upregulation of N‐cadherin was associated with worse 5‐year survival in HNC (HR = 1.87, 95%CI \[1.05, 3.33\]) and cancer of digestive system (HR = 1.66, 95%CI \[1.13, 2.44\]). Considering the heterogeneity, a fixed effect model and a random effect model were performed in 3‐year (*I* ^2^ = 29.4%, *P *=* *.174) and 5‐year survival analysis (*I* ^2^ = 58.2%, *P *=* *.019), respectively.

![Forrest plots of hazard ratios (HRs) for correlation between N‐cadherin upregulation and survival outcomes. A, 3‐year survival; B, 5‐year survival; C, overall survival (OS)](ECI-48-na-g004){#eci12903-fig-0004}

3.8. Overall survival {#eci12903-sec-0019}
---------------------

N‐cadherin upregulation was proved to have a significant association with worse OS, with pooled HR = 1.32 (95% CI \[1.20, 1.44\]), in 22 studies with 4081 patients (Figure [4](#eci12903-fig-0004){ref-type="fig"}C).[33](#eci12903-bib-0033){ref-type="ref"}, [41](#eci12903-bib-0041){ref-type="ref"}, [42](#eci12903-bib-0042){ref-type="ref"}, [43](#eci12903-bib-0043){ref-type="ref"}, [44](#eci12903-bib-0044){ref-type="ref"}, [45](#eci12903-bib-0045){ref-type="ref"}, [46](#eci12903-bib-0046){ref-type="ref"}, [49](#eci12903-bib-0049){ref-type="ref"}, [50](#eci12903-bib-0050){ref-type="ref"}, [52](#eci12903-bib-0052){ref-type="ref"}, [55](#eci12903-bib-0055){ref-type="ref"}, [58](#eci12903-bib-0058){ref-type="ref"}, [59](#eci12903-bib-0059){ref-type="ref"}, [60](#eci12903-bib-0060){ref-type="ref"}, [61](#eci12903-bib-0061){ref-type="ref"}, [62](#eci12903-bib-0062){ref-type="ref"}, [63](#eci12903-bib-0063){ref-type="ref"}, [64](#eci12903-bib-0064){ref-type="ref"}, [65](#eci12903-bib-0065){ref-type="ref"}, [66](#eci12903-bib-0066){ref-type="ref"}, [67](#eci12903-bib-0067){ref-type="ref"}, [68](#eci12903-bib-0068){ref-type="ref"} According to subgroup analyses of different cancer types, N‐cadherin upregulation in breast cancer (HR = 1.40, 95% CI \[1.22, 1.61\]), NSCLC (HR = 1.56, 95% CI \[1.26, 1.93\]) (n = 6, with 748 patients) and cancers of digestive system (HR = 1.42, 95% CI \[1.10, 1.85\]) (n = 5, with 406 patients) acted as an unfavourable indicator of OS. Due to no obvious heterogeneity was observed, a fixed effect model was performed (*I* ^2^ = 48.0%).

3.9. Publication bias {#eci12903-sec-0020}
---------------------

Both Begg\'s funnel plot and Egger\'s test were employed to evaluate the publication bias in all studies, including lymph node metastasis, histological grade, angiolymphatic invasion, distant metastasis, clinical stage, 3‐year and 5‐year survival and OS, respectively (Figure [5](#eci12903-fig-0005){ref-type="fig"}). In addition, Begg\'s funnel plot of molecular markers of breast cancer (ER, PR and HER2) was shown in Figure [S1](#eci12903-sup-0001){ref-type="supplementary-material"}B. Begg\'s funnel plot showed no statistically significant asymmetry in this meta‐analysis, involving lymph node metastasis (*P* = .629), histological grade (*P *=* *.763), angiolymphatic invasion (*P *=* *.322), distant metastasis (*P *=* *.652), clinical stage (*P *=* *.477), 3‐year and 5‐year survival and OS (*P *=* *.655, *P *=* *.216, *P *=* *.933, respectively). Furthermore, no evidence of publication bias was observed in Egger\'s test of lymph node metastasis (*P *=* *.735), histological grade (*P *=* *.115), angiolymphatic invasion (*P *=* *.159), clinical stage (*P *=* *.772), 3‐year and 5‐year survival and OS (*P *=* *.920, *P *=* *.492, *P *=* *.634, respectively), and molecular makers of breast cancer (*P *=* *.741). Egger\'s test showed potential publication bias in analysis of distant metastasis (*P *=* *.023).

![Funnel graph for assessing the potential publication bias of this meta‐analysis. A, Lymph node metastasis; B, histological grade; C, angiolymphatic invasion; D, distant metastasis; E, clinical stage; F, 3‐year and 5‐year survivals; G, overall survival (OS)](ECI-48-na-g005){#eci12903-fig-0005}

4. DISCUSSION {#eci12903-sec-0021}
=============

Many laboratorial evidences have revealed that N‐cadherin could drive tumour cells to move into surrounding stroma, thereby promoting tumour cells migration, invasion and metastasis.[15](#eci12903-bib-0015){ref-type="ref"}, [18](#eci12903-bib-0018){ref-type="ref"}, [20](#eci12903-bib-0020){ref-type="ref"}, [69](#eci12903-bib-0069){ref-type="ref"} In addition, the upregulation of N‐cadherin was also noticed in different cancer types and was also hinted to link to higher histological grade and metastatic tendency.[69](#eci12903-bib-0069){ref-type="ref"}, [70](#eci12903-bib-0070){ref-type="ref"}, [71](#eci12903-bib-0071){ref-type="ref"} Hence, N‐cadherin has been implicated as potential target for anticancer therapy.[72](#eci12903-bib-0072){ref-type="ref"} Monoclonal antibody targeting of N‐cadherin has been reported to be effective in inhibiting proliferation, metastasis and castration resistance of prostate cancer.[10](#eci12903-bib-0010){ref-type="ref"} Moreover, a kind of N‐cadherin antagonist has been developed by researchers, a synthetic cyclic pentapeptide (known as ADH‐1). In an animal model of pancreatic cancer, ADH‐1 showed the inhibitory effect against tumour growth and metastasis.[73](#eci12903-bib-0073){ref-type="ref"} Importantly, a phase I/II clinical trial has shown combination of ADH‐1 and melphalan could suppress tumour growth in patients with locally advanced melanoma.[74](#eci12903-bib-0074){ref-type="ref"} Furthermore, ADH‐1 was evaluated to be well tolerable both in animal models and humans.[75](#eci12903-bib-0075){ref-type="ref"}, [76](#eci12903-bib-0076){ref-type="ref"} However, according to current clinical evidences, the clinical significance of N‐cadherin still was unclear. The majority of studies demonstrated N‐cadherin as an unfavourable prognostic marker in a variety of tumours, while some studies showed the tumour suppressor role of N‐cadherin. Therefore, an integrated study is urgently needed to answer this question.

As far as we know, this study is the first comprehensive and most full‐scale meta‐analysis to investigate the prognostic value of N‐cadherin upregulation in epithelial‐derived solid tumours. At the beginning, 38 studies were involved in this meta‐analysis, while 2 studies were about nonepithelial solid tumours, including melanoma and sarcoma.[77](#eci12903-bib-0077){ref-type="ref"}, [78](#eci12903-bib-0078){ref-type="ref"} Thus, we excluded these 2 studies for making our conclusions more applicable to epithelia‐derived solid tumours. In summary, upregulation of N‐cadherin was shown to be significantly associated with lymph node metastasis, higher histological grade, angiolymphatic invasion and advanced clinical stage. According to different cancer types, subgroup analyses further explored relationships between some special cancer types and clinicopathological features. Results suggested upregulation of N‐cadherin was associated with lymph node metastasis in prostate cancer, higher histological grade in breast cancer, advanced clinical stage in HNC, positive angiolymphatic invasion and distant metastasis in cancers of digestive system. Importantly, pooled HRs showed upregulation of N‐cadherin was an obvious unfavourably prognostic factor in analyses of 3‐year survival, 5‐year survival and OS, especially for NSCLC and cancers of digestive system according to results from subgroup analyses of OS. Therefore, patients with higher N‐cadherin expression may need more aggressive treatment, especially for NSCLC and cancers of digestive system.

In spite of the inspiring outcomes, some limitations could not be ignored. First, although all of the included studies used IHC method to measure expression level of N‐cadherin, different antibody sources or various cut‐off values could lead to potential bias. However, limited by insufficient number of studies, the subgroup analyses of antibody sources or cut‐off values were unable to be carried out. Second, obvious heterogeneity was existed in analyses of lymph node metastasis, histological grade, clinical stage, 5‐year survival and OS, which may be derived from different cancer types, cancer stages, follow‐up time, etc. Random effect model was employed to reduce the effect of heterogeneity on outcomes. In addition, corresponding subgroup analyses were also conducted to make outcomes more reliable and decrease potential bias. Finally, it would be better if we could conduct a comprehensive analysis about prognostic value of cadherin switching in tumours. Loss of E‐cadherin always accompanied with upregulation of N‐cadherin in tumours. Besides, loss of E‐cadherin has been proved to be associated with unfavourable outcomes in various tumours.[79](#eci12903-bib-0079){ref-type="ref"}, [80](#eci12903-bib-0080){ref-type="ref"}, [81](#eci12903-bib-0081){ref-type="ref"}, [82](#eci12903-bib-0082){ref-type="ref"} The analysis in combination of E‐cadherin and N‐cadherin might be more valuable in prognostic evaluation of some special tumours, while only a few studies assessed the impact of cadherin switching.[83](#eci12903-bib-0083){ref-type="ref"}

In conclusion, our study suggests that positivity of N‐cadherin is associated with more aggressive behaviour of epithelial‐derived solid malignancies, linked to lymph node metastasis, higher histological grade, angiolymphatic invasion and advanced clinical stage. Moreover, N‐cadherin could be regarded as a useful predictor for unfavourable prognosis of 3‐year survival, 5‐year survival and OS in epithelial‐derived solid malignancies. The expression status of N‐cadherin can provide a reference for treatment strategy and prognostic prediction of epithelial‐derived solid malignancies.
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